High prevalence of metabolic syndrome in takayasu arteritis: Increased cardiovascular risk and lower adiponectin serum levels

Journal of Rheumatology

Volumn 40, Issue 11, 2013, Pages 1897-1904

  Da Silva, Thiago Ferreira ^a   Maurício, Levy Neto ^a   Bonfá, Eloisa ^a   Pereira, Rosa Maria R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ADIPONECTIN; METABOLIC SYNDROME; MORTALITY; PREVALENCE; TAKAYASU ARTERITIS

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN E; C REACTIVE PROTEIN; GLUCOCORTICOID; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AORTA ARCH SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; METABOLIC SYNDROME; MORTALITY; PREVALENCE; TAKAYASU ARTERITIS;

ADIPONECTIN; ADULT; CARDIOVASCULAR DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK; TAKAYASU ARTERITIS;

EID: 84887487575     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130162     Document Type: Article

References (47)

1. Pereira RM, Carvalho JF, Bonfá E. Metabolic syndrome in rheumatological diseases. Autoimmun Rev 2009;8:415-9.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
3. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between auto-immune diseases and atherosclerosis. Autoimmun Rev 2006;5:331-7.
4. Pincus T, Callahan LF. Taking mortality in rheumatic arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13:841-5.
5. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
6. Cohen Tervaert JW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol 2013;27:33-44.
7. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55:1537-45.
8. Scotece M, Conde J, Gómez R, López V, Lago F, Gómez-Reino JJ, et al. Beyond Fat Mass: exploring the role of adipokines in rheumatic diseases. Scientific World Journal 2011;11:1932-47.
9. Tann OR, Tulloh RM, Hamilton MC. Takayasu's disease: a review. Cardiol Young 2008;18:250-9.
10. Carvalho JF, Bonfa E, Bezerra MC, Pereira RMR. High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis. Clin Rheumatol 2009;28:801-5.
11. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-34.
12. Alberti KG, Zimmet PZ, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
13. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
14. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med 1994;120:919-29.
15. Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, Pereira RM. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology 2005;44:1503-6.
16. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
17. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983;29:1075-80.
18. Warnick GR, Cheung NC, Albers JJ. Comparison of current methods for high density lipoprotein cholesterol quantification. Clin Chem 1979;25:596-604.
19. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
20. Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006;33:1545-52.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
22. Yokoyama H, Hirose H, Ohgo H, Saito I. Associations among lifestyle, serum adiponectin level and insulin resistance. Intern Med 2004;43:453-7.
23. Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes 2012;61:1315-22.
24. Dutra ES, de Carvalho KM, Miyazaki E, Hamann EM, Ito MK. Metabolic syndrome in central Brazil: prevalence and correlates in the adult population. Diabetol Metab Syndr 2012;4:20.
25. Marquezine GF, Oliveira CM, Pereira AC, Krieger JE, Mill JG. Metabolic syndrome determinants in an urban population from Brazil: social class and gender-specific interaction. Int J Cardiol 2008;129:259-65.
26. Azevedo GD, Gadelha RG, Vilar MJ. Metabolic syndrome in systemic lupus erythematosus: lower prevalence in Brazil than in the USA. Ann Rheum Dis 2007;66:1542.
27. Sabio J, Zamora-Pasadas M, Jiménez-Jáimez J, Albadalejo F, Vargas-Hitos J, Rodríguez Del Aguila M, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008;17:849-59.
28. Bultink IE, Turkstra F, Diamant M, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol 2008;26:32-8.
29. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 2007;66:28-33.
30. Ramos-Casals M, Brito-Zerón P, Sisó A, Vargas A, Ros E, Bove A, et al. High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression. J Rheumatol 2007;34:54-61.
31. Rodrigues CE, Bonfá E, Caleiro MT, Vendramini MB, Bueno C, Lopes JB, et al. Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome. Arthritis Care Res 2012;64:1576-83.
32. Petermann Smits DR, Wilde B, Kianersi Adegani M, de Jongh H, van Paassen P, Cohen Tervaert JW. Metabolic syndrome in ANCA-associated vasculitis. Rheumatology 2013;52:197-203.
33. Gremese E, Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011;10:582-9.
34. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789-95.
35. Kemmotsu Y, Saji T, Kusunoki N, Tanaka N, Nishimura C, Ishiguro A, et al. Serum adipokine profiles in Kawasaki disease. Mod Rheumatol 2012;22:66-72.
36. Kim SK, Choe JY, Park SH, Lee SW, Lee GH, Chung WT. Increased insulin resistance and serum resistin in Korean patients with Behçet's disease. Arch Med Res 2010;41:269-74.
37. Almehed K, d'Elia HF, Bokarewa M, Carlsten H. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther 2008;10:R15.
38. Senolt L, Housa D, Vernerová Z, Jirásek T, Svobodová R, Veigl D, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007;66:458-63.
39. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 2009;43:157-68.
40. Lago F, Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Gualillo O. Cardiometabolic comorbidities and rheumatic diseases: focus on the role of fat mass and adipokines. Arthritis Care Res 2011;63:1083-90.
41. Sanjari M, Khodashahi M, Gholamhoseinian A, Shokoohi M. Association of adiponectin and metabolic syndrome in women. J Res Med Sci 2011;16:1532-40.
42. Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, Mediavilla JD, Navarrete N, Ramirez A, et al. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 2009;36:2204-11.
43. Bellomio V, Spindler A, Lucero E, Berman A, Sueldo R, Berman H, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 2009;18:1019-25.
44. Cunha VR, Brenol CV, Brenol JC, Fuchs SC, Arlindo EM, Melo IM, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol 2012;41:186-91.
45. Toms TE, Panoulas VF, Douglas KM, Griffiths HR, Kitas GD. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2008;10:R145.
46. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999;100:55-60.
47. Sun Y, Ma L, Yan F, Liu H, Ding Y, Hou J, et al. MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu's arteritis. Int J Cardiol 2012;156:236-8.